drugset / Trial / NCT00565474

Evaluation of the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vasculopathy of the Graft in de Novo Renal Transplant Patients Transplant

NCT00565474

Phase 4 Completed 84 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindPrevention

Summary

Principal objective is to investigate if the treatment with fluvastatin can prevent the progression of vascular graft disease in de novo renal transplant patients.

Timeline

Start
2001-09
Primary completion
2007-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluvastatin Other / unclassified 40 mg